Terapia intravítrea con aflibercept en ojos con coriorretinopatía serosa central crónica: resultados a corto plazo / Intravitreal aflibercept therapy in eyes with chronic central serous chorioretihopathy: Short term results

OBJETIVOS: Evaluar la eficacia a corto plazo y los resultados de tolerabilidad de la inyección intravítrea de aflibercept como opción de tratamiento para ojos con coriorretinopatía serosa central (CSC) crónica. MATERIAL Y MÉTODOS: Estudio prospectivo longitudinal de 10 ojos de 10 pacientes con CSC crónica con un seguimiento de > 6 meses después de la primera inyección intravítrea de aflibercept. Los valores de mejor agudeza visual corregida (MAVC) y del espesor macular central (EMC) -este último obtenido por tomografía de coherencia óptica de dominio espectral- se registraron al inicio y al primer, tercer y sexto mes desde la inyección. RESULTADOS: La MAVC logMAR media fue de 0,70 ± 0,25 al inicio. A los meses 1, 3 y 6 después de la inyección, la MAVC logMAR media fue de 0,39 ± 0,36, 0,32 ± 0,39 y 0,29 ± 0,34, respectivamente. La MAVC media y mediana a través de todo el período de seguimiento mejoró de forma significativa con respecto a la MAVC de inicio (p < 0,05 para cada una). El EMC medio fue de 449,30 ± 142,53 μm al inicio. Las mediciones tomadas el primer mes fueron de 302,60 ± 72,2 8 μm, el tercer mes de 294,30 ± 72,85 μm, y de 294,60 ± 83,84 μm el sexto mes después de la inyección. El EMC medio y mediano durante todo el período de seguimiento disminuyó considerablemente con respecto al EMC de inicio (p < 0,05 para cada uno). Ninguno de los pacientes sufrió efectos secundarios oculares o sistémicos graves a lo largo del estudio. CONCLUSIONES: Los resultados de corto plazo de este estudio demuestran que puede utilizarse aflibercept intravítreo como opción de tratamiento para mejorar la MAVC y reducir el EMC en la CSC crónica

OBJECTIVES: To evaluate the short term efficacy and tolerability results of intravitreal aflibercept injection as a treatment option for eyes with chronic central serous chorioretinopathy (CSCR). MATERIAL AND METHODS: A prospective longitudinal study. Ten eyes of 10 patients with chronic CSCR who had been followed for >6months after the first intravitreal injection of aflibercept were recruited for the study. The best corrected visual acuity (BCVA) and central macular thickness (CMT) values obtained by spectral-domain optical coherence tomography were recorded at baseline and the first, third, and sixth months after the injection. RESULTS: The mean logMAR BCVA was 0.70 ± 0.25 at baseline. At the first, third, and sixth months after the injection, the mean logMAR BCVA were 0.39 ± 0.36, 0.32 ± 0.39, and 0.29 ± 0.34, respectively. The mean and median BCVA over the entire follow-up period was significantly improved compared with baseline BCVA (P < .05 for each one). The mean CMT was 449.30 ± 142.53 μm at baseline. It was measured as 302.60 ± 72.28 μm on the first month, 294.30 ± 72.85 μm on the third month, and 294.60 ± 83.84 μm on the sixth month after the injection. The mean and median CMT during the entire follow-up period was significantly decreased compared with baseline CMT (P < .05 for each one). None of the patients had any serious ocular or systemic side effects over the course of the study. CONCLUSIONS: Short term results of this study demonstrate that intravitreal aflibercept may be used as a treatment option to improve the BCVA and reduce the CMT in chronic CSCR

Intravitreal aflibercept therapy in eyes with chronic central serous chorioretihopathy: Short term results. / Terapia intravítrea con aflibercept en ojos con coriorretinopatía serosa central crónica: resultados a corto plazo.

OBJECTIVES: To evaluate the short term efficacy and tolerability results of intravitreal aflibercept injection as a treatment option for eyes with chronic central serous chorioretinopathy (CSCR). MATERIAL AND METHODS: A prospective longitudinal study. Ten eyes of 10 patients with chronic CSCR who had been followed for >6months after the first intravitreal injection of aflibercept were recruited for the study. The best corrected visual acuity (BCVA) and central macular thickness (CMT) values obtained by spectral-domain optical coherence tomography were recorded at baseline and the first, third, and sixth months after the injection. RESULTS: The mean logMAR BCVA was 0.70±0.25 at baseline. At the first, third, and sixth months after the injection, the mean logMAR BCVA were 0.39±0.36, 0.32±0.39, and 0.29±0.34, respectively. The mean and median BCVA over the entire follow-up period was significantly improved compared with baseline BCVA (P<.05 for each one). The mean CMT was 449.30±142.53µm at baseline. It was measured as 302.60±72.28µm on the first month, 294.30±72.85µm on the third month, and 294.60±83.84µm on the sixth month after the injection. The mean and median CMT during the entire follow-up period was significantly decreased compared with baseline CMT (P<.05 for each one). None of the patients had any serious ocular or systemic side effects over the course of the study. CONCLUSIONS: Short term results of this study demonstrate that intravitreal aflibercept may be used as a treatment option to improve the BCVA and reduce the CMT in chronic CSCR.